Beryl Drugs Limited (524606) Fair Value & Analysis
Healthcare · IN · Market cap ₹30.6M
Fair value as of: Jul 4, 2026
From 13 valuation models · updated today
Share price −0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹16.87 – ₹28.09 · fair‑value band ₹13.82 – ₹19.01 · the ₹21.22 price screens above the ₹17.12 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Beryl Drugs Limited (524606) currently trades at ₹21.22, while our model-based Fair Value estimate is ₹17.12 — implying the stock looks roughly 19.3% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Beryl Drugs Limited generated revenue of ₹113M at a net margin of -4.4%. Revenue declined 36.3% year over year. Net debt stands at ₹21.2M. The stock trades on a trailing P/E of 4.6. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers I.V. fluids and small volume injectables, as well as veterinary products. It also provides research and development, and contract manufacturing services. Beryl Drugs Limited was founded in 1993 and is based in Indore, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Beryl Drugs Limited reported revenue of ₹188M in FY2026 versus ₹145M in FY2022, a compound +6.8%/yr. Reported net income was ₹4.2M in FY2026.
Is 524606 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beryl Drugs Limited (524606) undervalued?
What is the fair value of 524606?
What is the quality score of 524606?
What is the revenue of Beryl Drugs Limited (524606)?
What is the net profit margin of 524606?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.